Private company

Calliditas Therapeutics AB

Last updated Oct 16, 2026.

Overview

-466.2MNet income, fiscal 20232
  • IndustryPharmaceutical Preparations
  • HeadquartersV7
  • Incorporated inSweden3
  • Business addressKungsbron 1, D5, Stockholm, V7 Se-111 223
  • Filer categoryAccelerated filer3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-$447.4MFree cash flow2

Financial statements

Gross profit42$1.1B in 2023+131070% since 2020
0$500.0M$1.0B$1.5B2020: $874.0K$874.0K20202021: $229.3M$229.3M2021+26141%2022: $787.7M$787.7M2022+243%2023: $1.1B$1.1B2023+46%
Operating income5642-$373.1M in 2023+182% since 2018
-$600.0M-$400.0M-$200.0M02018: -$132.5M-$132.5M20182019: -$28.0M-$28.0M2019−79%2020: -$379.7M-$379.7M2020+1255%2021: -$524.5M-$524.5M2021+38%2022: -$421.9M-$421.9M2022−20%2023: -$373.1M-$373.1M2023−12%
Net income5642-$466.2M in 2023+253% since 2018
-$600.0M-$400.0M-$200.0M02018: -$132.0M-$132.0M20182019: -$32.6M-$32.6M2019−75%2020: -$436.5M-$436.5M2020+1240%2021: -$509.5M-$509.5M2021+17%2022: -$412.3M-$412.3M2022−19%2023: -$466.2M-$466.2M2023+13%
Fiscal year2017201820192020202120222023
Gross profit874.0K SEK4229.3M SEK2787.7M SEK21.1B SEK2
Operating income-132.5M SEK5-28.0M SEK6-379.7M SEK4-524.5M SEK2-421.9M SEK2-373.1M SEK2
Net income-132.0M SEK5-32.6M SEK6-436.5M SEK4-509.5M SEK2-412.3M SEK2-466.2M SEK2
Earnings per share-$0.886-$9.666-$9.846

Compare Calliditas Therapeutics AB with another company

Recent filings

  1. Sep 3, 20246-K
  2. Aug 13, 20246-K
  3. Jul 31, 20246-K
  4. Jul 26, 20246-K
  5. Jun 17, 20246-K
  6. May 30, 20246-K
  7. May 28, 20246-K
  8. May 23, 20246-K
  9. May 16, 20246-K
  10. May 6, 20246-K
  11. Apr 25, 20246-K
  12. Apr 24, 202420-F
  13. Mar 6, 20246-K
  14. Feb 21, 20246-K
  15. Jan 8, 20246-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1